1
Engineered biology is leaving the workbench for living systems
As genome editors, synthetic assemblies and delivery vehicles approach real applications, reliability becomes the central biological question.
Synthetic Biology brings the most explicit shift from parts to programs. Recent selections on functional protein design from natural language and bottom-up RNA transfer vehicles treat engineered biology as a design discipline, but the biological question remains whether the constructs behave predictably inside living systems.
Genetic Engineering Publications adds the therapeutic pressure test. A base-editing study in a mouse model of Hutchinson-Gilford progeria syndrome and reports on in vivo CRISPR therapy show editing moving closer to patients, where delivery, dose, off-target activity and durability matter as much as molecular elegance.
RMH and I2BC Paris-Saclay widen the frame beyond standard tool papers. An engineered CasX editor points to optimization for therapeutic use, while CRISPR-Cas12a editing in a non-model cyanobacterium shows the same reliability problem in microbial systems that are harder to domesticate.
Across these topics, the story is no longer simply that genomes can be rewritten. The harder question is how to make edits, transfers and synthetic assemblies controllable enough for medicine, microbiology and future biological production.
Further reading